Dogwood Therapeutics Inc (DWTX) Stock Price, Quote & News

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a co...

Industry: Biotechnology

Sector: Healthcare

Phone: 866 620 8655

Website: dwtx.com

Address:

44 Milton Avenue, Alpharetta, United States

ThatEscalatedQuickly May. 25 at 3:09 PM

$SBFM $FEMY $GOVX $ESLA $DWTX Have you ever dreampt a play squeezes and then you wake ⏰️ up & check your device 🙄 I just dreampt $SBFM was at 1, my heart was racing 👀📈 in a good way 👍🏼 Check back later 😎💰🔥 Let's go Bullz!

1 · Reply

ThatEscalatedQuickly May. 25 at 12:14 PM

$SBFM $GOVX $FEMY $ESLA $DWTX $SBFM ▶️ moving away from news, pipeline, 13G filings, offerings, etc. Here is the technical set up i like 👍🏼 Post offering sell off, we have a reversal with a bull pennant, followed by a bull flag later in the week. Friday was 8 consecutive days closing under $1. I think $SBFM is safe for the next 10 training days Good luck Bulls 👍🏼

0 · Reply

ThatEscalatedQuickly May. 25 at 1:40 AM

$SBFM $GOVX $FEMY Holding Watching 👀 $ESLA $DWTX now with recent 13G filings

0 · Reply

focafoca99 May. 18 at 1:01 PM

$DWTX commences a Phase 2b extension study of its Halneuron® chemotherapy‑induced neuropathic pain program.

0 · Reply

johnny6nine May. 18 at 12:46 PM

$DWTX https://ir.dwtx.com/news/press-releases/detail/156/dogwood-therapeutics-announces-commencement-of-halneuron

0 · Reply

Complys May. 14 at 9:17 PM

$DWTX

0 · Reply

Drainomight May. 14 at 8:17 PM

$DWTX up from here

0 · Reply

BiotechGoldenEra May. 5 at 2:24 AM

$DWTX dod feces

1 · Reply

Drainomight May. 4 at 2:43 PM

$DWTX

0 · Reply

OfficialStocktwitsUser May. 4 at 2:25 PM

$DWTX RSI: 32.19, MACD: -0.2487 Vol: 0.24, MA20: 1.62, MA50: 2.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Dogwood begins Phase 2b extension study for Halneuron

May 18, 2026, 8:45 AM EDT - 9 days ago

Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study

May 14, 2026, 9:30 AM EDT - 13 days ago

Dogwood Therapeutics Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 13 days ago

Dogwood Therapeutics Quarterly report: Q1 2026

May 14, 2026, 8:30 AM EDT - 13 days ago

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

May 12, 2026, 2:00 AM EDT - 15 days ago

Dogwood Therapeutics Slides: Corporate presentation

May 7, 2026, 8:30 AM EDT - 20 days ago

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Apr 27, 2026, 8:00 AM EDT - 4 weeks ago

Dogwood Therapeutics Proxy statement: Proxy filing

2026-04-23T13:30:03.000Z - 4 weeks ago

Dogwood announces commercialization partnership with PRIDCor

Apr 23, 2026, 9:00 AM EDT - 4 weeks ago

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Apr 17, 2026, 8:00 AM EDT - 5 weeks ago

Dogwood Therapeutics Proxy statement: Proxy filing

2026-04-15T13:22:56.000Z - 6 weeks ago

Dogwood announces FDA acceptance of SP16 investigational new drug application

Apr 15, 2026, 9:00 AM EDT - 6 weeks ago

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Mar 18, 2026, 9:00 AM EDT - 2 months ago

Dogwood Therapeutics Annual report: Q4 2025

Mar 18, 2026, 9:00 AM EDT - 2 months ago

Dogwood Therapeutics Earnings release: Q4 2025

2026-03-18T12:42:15.000Z - 2 months ago

Dogwood sees cash runway into 4Q26

Mar 18, 2026, 8:30 AM EDT - 2 months ago

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 13, 2026, 7:00 AM EST - 3 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2026-02-02T13:35:35.000Z - 4 months ago

Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial

Feb 2, 2026, 8:30 AM EST - 4 months ago

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Jan 26, 2026, 6:00 AM EST - 4 months ago

Dogwood Therapeutics Slides: Investor presentation

Jan 23, 2026, 7:00 AM EST - 4 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2026-01-15T21:25:14.000Z - 4 months ago

Dogwood files to sell 6.43M shares of common stock for holders

Jan 15, 2026, 7:00 AM EST - 4 months ago

Dogwood Therapeutics Registration statement: Registration Filing

2026-01-12T13:55:35.000Z - 4 months ago

Dogwood announces financing of up to $26.8M

Jan 12, 2026, 8:30 AM EST - 4 months ago

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

2025-12-22T15:20:25.000Z - 5 months ago

Dogwood announces interim Phase 2b trial results on Halneuron

Dec 22, 2025, 10:15 AM EST - 5 months ago

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

2025-12-02T13:30:43.000Z - 6 months ago

Dogwood files for IP protection for synthetic Halneuron

Dec 2, 2025, 8:00 AM EST - 6 months ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Nov 21, 2025, 10:00 AM EST - 6 months ago

Dogwood Therapeutics Transcript: EGM 2025

2025-11-11T13:55:32.000Z - 7 months ago

Dogwood enrolls first 100 patients in Halneuron Phase 2b trial

Nov 11, 2025, 8:45 AM EST - 7 months ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 6, 2025, 8:45 AM EST - 7 months ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 7 months ago

Dogwood Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Dogwood Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 9:15 AM EDT - 7 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 16, 2025, 8:00 AM EDT - 7 months ago

Dogwood Therapeutics Registration statement: Registration Filing

Oct 14, 2025, 8:45 AM EDT - 8 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 9, 2025, 8:00 AM EDT - 8 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 8, 2025, 8:00 AM EDT - 8 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2025-10-07T13:30:11.000Z - 8 months ago

Dogwood to present on Halneuron pain research program

Oct 7, 2025, 8:45 AM EDT - 8 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

2025-10-01T20:20:32.000Z - 8 months ago

Dogwood files to sell 28.04M shares of common stock for holders

Oct 1, 2025, 8:00 AM EDT - 8 months ago

Dogwood Therapeutics Registration statement: Registration Filing

2025-09-30T10:15:45.000Z - 8 months ago

Dogwood price target raised to $12 from $10 at H.C. Wainwright

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Dogwood Therapeutics Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Dogwood Therapeutics Press release: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Dogwood Therapeutics Slides: Study Update

Sep 29, 2025, 8:00 AM EDT - 8 months ago

Dogwood Therapeutics Proxy statement: Proxy Filing

2025-09-29T11:20:42.000Z - 8 months ago

Dogwood secures royalty free license to develop, commercialize SP16

Sep 29, 2025, 7:15 AM EDT - 8 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Dogwood Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 9 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 13, 2025, 9:30 AM EDT - 10 months ago

Dogwood Therapeutics Quarterly report: Q2 2025

Aug 13, 2025, 9:30 AM EDT - 10 months ago

Dogwood Therapeutics Earnings release: Q2 2025

Aug 13, 2025, 9:00 AM EDT - 10 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 6:00 PM EDT - 10 months ago

Dogwood Therapeutics Slides: Corporate Presentation

Aug 7, 2025, 1:08 PM EDT - 10 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 6, 2025, 9:15 AM EDT - 10 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Jun 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Sidoti's Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

2025-05-23T21:30:13.000Z - 1 year ago

Dogwood files $150M mixed securities shelf

May 23, 2025, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Registration statement: Registration Filing

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Quarterly report: Q1 2025

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q1 2025

May 1, 2025, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Mar 31, 2025, 3:45 PM EDT - 1 year ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 1:30 PM EDT - 1 year ago

Dogwood Therapeutics Annual report: Q4 2024

Mar 31, 2025, 1:30 PM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q4 2024

Mar 18, 2025, 8:45 AM EDT - 1 year ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 13, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Earnings release: Q3 2024

Oct 17, 2024, 9:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: M&A Announcement

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Press release: M&A Announcement

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Slides: M&A Announcement

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Dogwood Therapeutics Quarterly report: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 1 year ago

Dogwood Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Jul 23, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

May 22, 2024, 1:30 PM EDT - 2 years ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 2 years ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 2 years ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings release: Q1 2024

May 9, 2024, 7:45 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 2, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Apr 25, 2024, 8:00 AM EDT - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Mar 26, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Feb 29, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 8:00 AM EST - 2 years ago

Dogwood Therapeutics Annual report: Q4 2023

Feb 29, 2024, 8:00 AM EST - 2 years ago

Dogwood Therapeutics Earnings release: Q4 2023

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 27, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Feb 2, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 7:00 AM EST - 2 years ago

Dogwood Therapeutics Proxy statement: Proxy Filing

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Quarterly report: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Earnings release: Q3 2023

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023, 8:30 AM EDT - 3 years ago

Dogwood Therapeutics Earnings Call Transcript: Q2 2023

Aug 10, 2023, 8:30 AM EDT - 3 years ago

Dogwood Therapeutics Quarterly report: Q2 2023

Aug 10, 2023, 8:30 AM EDT - 3 years ago

Dogwood Therapeutics Earnings release: Q2 2023

Aug 10, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

ThatEscalatedQuickly May. 25 at 3:09 PM

1 · Reply

ThatEscalatedQuickly May. 25 at 12:14 PM

0 · Reply

ThatEscalatedQuickly May. 25 at 1:40 AM

$SBFM $GOVX $FEMY Holding Watching 👀 $ESLA $DWTX now with recent 13G filings

0 · Reply

focafoca99 May. 18 at 1:01 PM

$DWTX commences a Phase 2b extension study of its Halneuron® chemotherapy‑induced neuropathic pain program.

0 · Reply

johnny6nine May. 18 at 12:46 PM

$DWTX https://ir.dwtx.com/news/press-releases/detail/156/dogwood-therapeutics-announces-commencement-of-halneuron

0 · Reply

Complys May. 14 at 9:17 PM

$DWTX

0 · Reply

Drainomight May. 14 at 8:17 PM

$DWTX up from here

0 · Reply

BiotechGoldenEra May. 5 at 2:24 AM

$DWTX dod feces

1 · Reply

Drainomight May. 4 at 2:43 PM

$DWTX

0 · Reply

OfficialStocktwitsUser May. 4 at 2:25 PM

0 · Reply

Drainomight Apr. 28 at 12:19 PM

$DWTX better days are coming

0 · Reply

hammerfall43 Apr. 24 at 3:14 PM

$DWTX Give me 1$ please

0 · Reply

MamawsBiscuits Apr. 23 at 9:28 PM

$DWTX hmmm

0 · Reply

DanielDiaz23 Apr. 23 at 7:23 PM

$DWTX why does it fall?

1 · Reply

focafoca99 Apr. 23 at 6:12 PM

$DWTX licensed IMC-1 and IMC-2 to PRIDCor in a worldwide partnership that could be worth up to $100 million plus royalties and other future economics.

0 · Reply

Drainomight Apr. 23 at 1:57 PM

$DWTX we should move up a little on the news

1 · Reply

hammerfall43 Apr. 23 at 1:21 PM

$DWTX

0 · Reply